Logo image of IDXX

IDEXX LABORATORIES INC (IDXX) Stock Fundamental Analysis

NASDAQ:IDXX - Nasdaq - US45168D1046 - Common Stock - Currency: USD

440.98  +14.35 (+3.36%)

After market: 440.98 0 (0%)

Fundamental Rating

7

Taking everything into account, IDXX scores 7 out of 10 in our fundamental rating. IDXX was compared to 191 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IDXX a very profitable company, without any liquidiy or solvency issues. IDXX has a decent growth rate and is not valued too expensively. With these ratings, IDXX could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

IDXX had positive earnings in the past year.
In the past year IDXX had a positive cash flow from operations.
IDXX had positive earnings in each of the past 5 years.
Each year in the past 5 years IDXX had a positive operating cash flow.
IDXX Yearly Net Income VS EBIT VS OCF VS FCFIDXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

The Return On Assets of IDXX (26.96%) is better than 98.95% of its industry peers.
Looking at the Return On Equity, with a value of 55.65%, IDXX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
With an excellent Return On Invested Capital value of 36.38%, IDXX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
IDXX had an Average Return On Invested Capital over the past 3 years of 35.08%. This is significantly above the industry average of 7.68%.
The last Return On Invested Capital (36.38%) for IDXX is above the 3 year average (35.08%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 26.96%
ROE 55.65%
ROIC 36.38%
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
IDXX Yearly ROA, ROE, ROICIDXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin of IDXX (22.78%) is better than 94.76% of its industry peers.
In the last couple of years the Profit Margin of IDXX has grown nicely.
Looking at the Operating Margin, with a value of 28.95%, IDXX belongs to the top of the industry, outperforming 97.38% of the companies in the same industry.
In the last couple of years the Operating Margin of IDXX has grown nicely.
IDXX's Gross Margin of 61.04% is fine compared to the rest of the industry. IDXX outperforms 61.26% of its industry peers.
In the last couple of years the Gross Margin of IDXX has remained more or less at the same level.
Industry RankSector Rank
OM 28.95%
PM (TTM) 22.78%
GM 61.04%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.55%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
IDXX Yearly Profit, Operating, Gross MarginsIDXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

8

2. Health

2.1 Basic Checks

IDXX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
IDXX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, IDXX has less shares outstanding
The debt/assets ratio for IDXX has been reduced compared to a year ago.
IDXX Yearly Shares OutstandingIDXX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IDXX Yearly Total Debt VS Total AssetsIDXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 16.92 indicates that IDXX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 16.92, IDXX belongs to the best of the industry, outperforming 95.29% of the companies in the same industry.
IDXX has a debt to FCF ratio of 1.09. This is a very positive value and a sign of high solvency as it would only need 1.09 years to pay back of all of its debts.
IDXX's Debt to FCF ratio of 1.09 is amongst the best of the industry. IDXX outperforms 92.67% of its industry peers.
IDXX has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
IDXX has a Debt to Equity ratio (0.44) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 1.09
Altman-Z 16.92
ROIC/WACC3.72
WACC9.77%
IDXX Yearly LT Debt VS Equity VS FCFIDXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

IDXX has a Current Ratio of 1.31. This is a normal value and indicates that IDXX is financially healthy and should not expect problems in meeting its short term obligations.
IDXX's Current ratio of 1.31 is on the low side compared to the rest of the industry. IDXX is outperformed by 76.44% of its industry peers.
A Quick Ratio of 0.95 indicates that IDXX may have some problems paying its short term obligations.
IDXX's Quick ratio of 0.95 is on the low side compared to the rest of the industry. IDXX is outperformed by 78.01% of its industry peers.
The current and quick ratio evaluation for IDXX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.31
Quick Ratio 0.95
IDXX Yearly Current Assets VS Current LiabilitesIDXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.72% over the past year.
IDXX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.18% yearly.
The Revenue has been growing slightly by 6.46% in the past year.
IDXX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.12% yearly.
EPS 1Y (TTM)11.72%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%12.93%
Revenue 1Y (TTM)6.46%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%5.84%

3.2 Future

The Earnings Per Share is expected to grow by 10.36% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.39% on average over the next years.
EPS Next Y8.67%
EPS Next 2Y10.64%
EPS Next 3Y11.3%
EPS Next 5Y10.36%
Revenue Next Year6.12%
Revenue Next 2Y6.92%
Revenue Next 3Y7.47%
Revenue Next 5Y7.39%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
IDXX Yearly Revenue VS EstimatesIDXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B
IDXX Yearly EPS VS EstimatesIDXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5 10 15 20

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 39.20, IDXX can be considered very expensive at the moment.
70.68% of the companies in the same industry are more expensive than IDXX, based on the Price/Earnings ratio.
IDXX is valuated rather expensively when we compare the Price/Earnings ratio to 28.92, which is the current average of the S&P500 Index.
IDXX is valuated quite expensively with a Price/Forward Earnings ratio of 36.07.
71.73% of the companies in the same industry are more expensive than IDXX, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of IDXX to the average of the S&P500 Index (21.65), we can say IDXX is valued expensively.
Industry RankSector Rank
PE 39.2
Fwd PE 36.07
IDXX Price Earnings VS Forward Price EarningsIDXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

69.11% of the companies in the same industry are more expensive than IDXX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than 74.35% of the companies in the same industry.
Industry RankSector Rank
P/FCF 44.78
EV/EBITDA 27.74
IDXX Per share dataIDXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
IDXX has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)4.52
PEG (5Y)2.16
EPS Next 2Y10.64%
EPS Next 3Y11.3%

0

5. Dividend

5.1 Amount

No dividends for IDXX!.
Industry RankSector Rank
Dividend Yield N/A

IDEXX LABORATORIES INC

NASDAQ:IDXX (4/24/2025, 8:17:30 PM)

After market: 440.98 0 (0%)

440.98

+14.35 (+3.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-03 2025-02-03/bmo
Earnings (Next)05-01 2025-05-01/bmo
Inst Owners91.99%
Inst Owner Change1.14%
Ins Owners0.18%
Ins Owner Change1.87%
Market Cap35.74B
Analysts78
Price Target522.16 (18.41%)
Short Float %3.4%
Short Ratio3.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.69%
Min EPS beat(2)2.49%
Max EPS beat(2)6.89%
EPS beat(4)4
Avg EPS beat(4)3.83%
Min EPS beat(4)2.49%
Max EPS beat(4)6.89%
EPS beat(8)8
Avg EPS beat(8)4.58%
EPS beat(12)10
Avg EPS beat(12)3.35%
EPS beat(16)14
Avg EPS beat(16)6.29%
Revenue beat(2)1
Avg Revenue beat(2)-1.13%
Min Revenue beat(2)-2.33%
Max Revenue beat(2)0.06%
Revenue beat(4)1
Avg Revenue beat(4)-1.65%
Min Revenue beat(4)-2.33%
Max Revenue beat(4)0.06%
Revenue beat(8)1
Avg Revenue beat(8)-1.58%
Revenue beat(12)1
Avg Revenue beat(12)-1.59%
Revenue beat(16)4
Avg Revenue beat(16)-0.79%
PT rev (1m)-0.12%
PT rev (3m)4.52%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)-4.37%
EPS NY rev (1m)0%
EPS NY rev (3m)0.03%
Revenue NQ rev (1m)-0.2%
Revenue NQ rev (3m)-2.02%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-0.99%
Valuation
Industry RankSector Rank
PE 39.2
Fwd PE 36.07
P/S 9.17
P/FCF 44.78
P/OCF 38.47
P/B 22.4
P/tB 33.13
EV/EBITDA 27.74
EPS(TTM)11.25
EY2.55%
EPS(NY)12.23
Fwd EY2.77%
FCF(TTM)9.85
FCFY2.23%
OCF(TTM)11.46
OCFY2.6%
SpS48.09
BVpS19.69
TBVpS13.31
PEG (NY)4.52
PEG (5Y)2.16
Profitability
Industry RankSector Rank
ROA 26.96%
ROE 55.65%
ROCE 50.7%
ROIC 36.38%
ROICexc 41.17%
ROICexgc 53.91%
OM 28.95%
PM (TTM) 22.78%
GM 61.04%
FCFM 20.48%
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
ROICexc(3y)39.8%
ROICexc(5y)41.54%
ROICexgc(3y)51.52%
ROICexgc(5y)54.69%
ROCE(3y)52.73%
ROCE(5y)50.92%
ROICexcg growth 3Y-5.99%
ROICexcg growth 5Y4.29%
ROICexc growth 3Y-3.86%
ROICexc growth 5Y4.07%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.55%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
F-Score8
Asset Turnover1.18
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 1.09
Debt/EBITDA 0.56
Cap/Depr 100.76%
Cap/Sales 3.36%
Interest Coverage 3.34
Cash Conversion 73.83%
Profit Quality 89.89%
Current Ratio 1.31
Quick Ratio 0.95
Altman-Z 16.92
F-Score8
WACC9.77%
ROIC/WACC3.72
Cap/Depr(3y)119.66%
Cap/Depr(5y)117.12%
Cap/Sales(3y)3.91%
Cap/Sales(5y)3.89%
Profit Quality(3y)79.31%
Profit Quality(5y)83.23%
High Growth Momentum
Growth
EPS 1Y (TTM)11.72%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%12.93%
EPS Next Y8.67%
EPS Next 2Y10.64%
EPS Next 3Y11.3%
EPS Next 5Y10.36%
Revenue 1Y (TTM)6.46%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%5.84%
Revenue Next Year6.12%
Revenue Next 2Y6.92%
Revenue Next 3Y7.47%
Revenue Next 5Y7.39%
EBIT growth 1Y2.85%
EBIT growth 3Y6.64%
EBIT growth 5Y15.38%
EBIT Next Year27.01%
EBIT Next 3Y14.52%
EBIT Next 5Y11.31%
FCF growth 1Y3.26%
FCF growth 3Y7.86%
FCF growth 5Y21.29%
OCF growth 1Y2.48%
OCF growth 3Y7.13%
OCF growth 5Y15.13%